

From Clinical Trial to Clinical Practice:

Demonstrating the Value of PCSK9 Inhibitors in Lipid Management Plans

Reference List

- (1) Lipinski MJ, Benedetto U, Escarcega RO, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. *Eur Heart J*. 2016;37(6):536-545.
- (2) Khan AR, Bavishi C, Riaz H, et al. Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. *Circ Cardiovasc Qual Outcomes*. 2017;10(1):e003153.
- (3) Robinson J, Rosenson RS, Farnier M, et al. Adverse events in patients with LDL-C <0.65 mmol/L (<25 mg/dL) or <0.39 mmol/L (<15 mg/dL) during alirocumab treatment for up to 104 weeks: data from 14 randomized trials. Abstract P1705. *Eur Heart J*. 2016;37(Suppl):341.
- (4) Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376(18):1713-1722.
- (5) Giugliano RP, Pedersen TR, De Ferrari GM, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. *Lancet*. 2017;doi:10.1016/S0140-6736(17)32290-0.
- (6) Praluent. [package insert]. Bridgewater, NJ, sanofi-aventis U.S. LLC; 2017.
- (7) Repatha. [package insert]. Thousand Oaks, CA, Amgen Inc.; 2017.
- (8) Symphony Health Solutions. PCSK9 inhibitors: Payer dynamics. Published February 10, 2017. Accessed August 30, 2017.
- (9) Navar AM, Taylor B, Flevitz E, et al. Early challenges for PCSK9 inhibitor prescriptions and patients: Rejections and rates unfilled. Abstract 415-08. Presented at: 2017 American College of Cardiology Scientific Session, Washington, DC, March 17-19, 2017.
- (10) Baum SJ, Toth PP, Underberg JA, Jellinger P, Ross J, Wilemon K. PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers. *Clin Cardiol*. 2017;40(4):243-254.
- (11) Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial. *JAMA*. 2016;316(22):2373-2384.
- (12) Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med*. 2015;372(16):1489-1499.
- (13) Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *J Am Coll Cardiol*. 2011;57(16):1666-1675.
- (14) Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *J Am Coll Cardiol*. 2014;64(5):485-494.
- (15) Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. *N Engl J Med*. 2014;370(19):1809-1819.
- (16) Ridker PM, Tardif JC, Amarenco P, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. *N Engl J Med*. 2017;376(16):1517-1526.
- (17) Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. *N Engl J Med*. 2017;376(16):1527-1539.

- (18) Roth EM, Goldberg AC, Catapano AL, et al. Antidrug antibodies in patients treated with alirocumab. *N Engl J Med.* 2017;376(16):1589-1590.
- (19) Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2014;63(25 Pt B):2889-2934.
- (20) Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. *J Clin Lipidol.* 2014;8(5):473-488.
- (21) Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol.* 2016;68(1):92-125.
- (22) Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. *Eur Heart J.* 2015;36(19):1186-1194.
- (23) Robinson JG, Huijgen R, Ray K, Persons J, Kastelein JJ, Pencina MJ. Determining when to add nonstatin therapy: A quantitative approach. *J Am Coll Cardiol.* 2016;68(22):2412-2421.